Insider Transactions in Q1 2021 at Fibrogen Inc (FGEN)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2021
|
Thomas F Kearns Jr Director |
SELL
Open market or private sale
|
Direct |
18,000
-10.83%
|
$630,000
$35.02 P/Share
|
|
Mar 11
2021
|
Thomas F Kearns Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+9.77%
|
$54,000
$3.5 P/Share
|
|
Mar 08
2021
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
5,679
-3.3%
|
$187,407
$33.37 P/Share
|
|
Mar 08
2021
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,657
-1.97%
|
$186,681
$33.37 P/Share
|
|
Mar 08
2021
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
SELL
Payment of exercise price or tax liability
|
Direct |
5,221
-3.42%
|
$172,293
$33.37 P/Share
|
|
Feb 24
2021
|
Enrique A Conterno Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,000
+37.4%
|
-
|
|
Feb 24
2021
|
Christine Chung SVP, CHINA OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
21,700
+11.19%
|
-
|
|
Feb 24
2021
|
Pat Cotroneo Executive Advisor & Former CFO |
BUY
Grant, award, or other acquisition
|
Direct |
21,700
+7.01%
|
-
|
|
Feb 24
2021
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
BUY
Grant, award, or other acquisition
|
Direct |
20,800
+12.0%
|
-
|
|
Feb 24
2021
|
Thane Wettig CEO |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+25.92%
|
-
|
|
Feb 17
2021
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
6,000
-7.84%
|
$312,000
$52.62 P/Share
|
|
Feb 17
2021
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+13.3%
|
$168,000
$28.65 P/Share
|
|
Jan 19
2021
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
6,000
-15.35%
|
$258,000
$43.38 P/Share
|
|
Jan 19
2021
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+13.3%
|
$114,000
$19.05 P/Share
|
|
Jan 14
2021
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
5,999
-15.34%
|
$239,960
$40.04 P/Share
|
|
Jan 14
2021
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,999
+13.3%
|
$113,981
$19.05 P/Share
|
|
Jan 06
2021
|
Enrique A Conterno Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,411
-8.92%
|
$205,618
$38.31 P/Share
|
|
Jan 04
2021
|
James A Schoeneck |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+28.04%
|
$54,000
$9.78 P/Share
|